Introduction
Stroke remains one of the leading causes of death and disability worldwide.[1] Due to ongoing demographic changes including aging of the population, its significance on a societal level is likely to increase over the next few years.
There are two main types of stroke: ischemic and hemorrhagic strokes. Ischemic strokes are more frequent and caused by a disruption of blood supply to certain brain regions leading to a lack of oxygen and subsequent loss of function and death of brain tissue. Depending on the location of affected brain areas, manifold clinical manifestations are possible.
The causes of ischemic stroke include thromboembolic, atherothrombotic, microangiopathic, and hemodynamic mechanisms. Stroke survivors are at increased risk of a recurrent stroke. Effective secondary prevention includes antiplatelet therapy, anticoagulation, and control of causal risk factors, and should be targeted to the underlying mechanism.
This review will focus on ischemic stroke in adults. Causes of stroke are largely attributable to age-dependent cardiovascular diseases and risk factors, and treatment of these risk factors is crucial in secondary prevention. In younger stroke patients (<45 years), the proportion of patients with other rare causes is higher than in the total stroke population. Therefore, these patients need specific attention and diagnostic evaluation.
Types of Brain Infarction
Territorial Infarct
Occlusion of a larger brain artery causes a territorial infarction, i.e., the death of the brain tissue supplied by the occluded artery. In most cases, such infarctions are caused by thromboembolism with thrombi stemming from larger upstream arteries, e.g., the carotid artery, or the heart. Occlusion resulting from local atherothrombosis, comparable to the mechanism of occlusion of coronary arteries leading to myocardial infarction, is much less common in the brain but may occur, e.g., in the presence of pre-existing intracranial stenosis. The middle cerebral artery territory is the most commonly affected territory due to the direct flow from the internal carotid artery ([Fig. 1A, B]). Patients with territorial kinds of infarcts often present with severe neurological syndromes.
Fig. 1 Most common types of brain infarction based on imaging classification. (A) Territorial right middle cerebral artery (MCA) infarct on CT-scan, (B) territorial right MCA infarct on fluid-attenuated inversion recovery (FLAIR) MRI, (C) acute lacunar infarct on diffusion-weighted MRI, and (D) acute hemodynamic right-sided infarcts on diffusion-weighted MRI.
Lacunar Infarct
Lacunar infarcts are small (<15 mm) noncortical infarcts ([Fig. 1C]). They are most commonly located in the deep nuclei of the brain (putamen, thalamus, and caudate) as well as the pons or the posterior limb of the internal capsule. Lacunar infarcts are a typical imaging hallmark of cerebral small-vessel disease (SVD; see below). With regard to the underlying pathology, it is assumed that lacunar strokes are mostly caused by an occlusion of small penetrating arteries due to lipohyalinosis and microatheroma,[3] which is in line with the high prevalence of risk factors such as arterial hypertension and diabetes mellitus in these patients. However, thromboembolism might also be a cause of occlusion of small penetrating arteries resulting in lacunar infarction, and patients with lacunar infarcts benefit from intravenous thrombolysis as well as patients with other stroke types.[4]
Hemodynamic Infarct
A hemodynamic stroke is a rare cause of stroke attributable to hypoperfusion of the brain ([Fig. 1D]). Hypoperfusion can be caused by severe local obstruction of an artery, such as carotid or vertebral stenosis, or by a systemic disease such as heart failure or cardiac arrest, or by the combination of both. The difference between hemodynamic strokes from other stroke subtypes is that ischemia occurs in an area of the brain that is at a distance from the blocked vessel. The clinical presentation of these patients often does not differ from those with other stroke subtypes. However, it is important that there might be precipitating circumstances of symptoms, e.g., orthostasis, hypotension, or cardiac arrhythmia.
Transient Ischemic Attack
A transient ischemic attack (TIA) is a brief episode of neurological symptoms caused by a focal cerebral ischemia. Therefore, a TIA and an ischemic stroke share the same underlying mechanisms; however, a TIA is not associated with permanent cerebral infarction. The definition of TIA is not consistent. Historically, TIA was defined solely based on the duration of symptoms (i.e., <24 hours), while more recently a “tissue-based” definition was suggested (i.e., transient symptoms with no evidence of infarction on imaging).[5] Due to the high risk of following stroke, a TIA needs equal diagnostic and secondary prevention as ischemic stroke with persistent symptoms.
Causes of Ischemic Stroke
The identification of the etiology of ischemic stroke is important to guide effective treatment and secondary prevention. Clinical presentation and appearance of lesions on brain imaging may already provide a clue to the underlying etiology (see types of brain infarction). A comprehensive diagnostic work-up is required to identify the underlying cause of stroke and vascular risk factors. Various classifications for ischemic stroke with regard to etiology are available. Most commonly used is the TOAST classification[6] which denotes five subtypes of ischemic stroke: (1) large-artery atherosclerosis (LAA), (2) cardiogenic embolism, (3) SVD, (4) stroke of other determined etiology, and (5) stroke of undetermined etiology ([Fig. 2]).
Fig. 2 Causes and distribution of ischemic stroke subtypes. (Modified from Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429–438.)
Large-Artery Atherosclerosis
LAA of intracranial or extracranial arteries is responsible for approximately 25% of all ischemic strokes. There are multiple factors contributing to the pathogenesis of atherosclerosis including inflammation, endothelial dysfunction, and classical cardiovascular risk factors such as hypertension, diabetes, hypercholesterolemia, and smoking. Strokes due to LAA are commonly caused by an artery-to-artery embolism or, less common, vessel stenosis resulting in hemodynamic infarctions. On neuroimaging, these strokes then present with a territorial or hemodynamic distribution pattern.
Cardiogenic Embolism
Cardiogenic embolism accounts for approximately 20% of ischemic strokes. A cardiogenic embolism results from a cardiac blood clot that enters the bloodstream and subsequently occludes a cerebral artery. The most frequent cause is atrial fibrillation (AF) with blood clots typically formed in the left atrial appendage. Moreover, heart failure, patent foramen ovale (PFO), or prosthetic heart valves are risk factors for cardioembolic strokes. It has been shown that cardiogenic embolism causes more severe strokes than other ischemic stroke subtypes.[7] On imaging, cardioembolic strokes usually present as territorial infarcts and may occur in more than one arterial territory and even bilaterally.
Small-Vessel Disease
Cerebral SVD is one of the three most common causes of ischemic stroke responsible for approximately 25% of ischemic strokes. SVD is a term used to describe a pathology affecting the microvasculature of the brain. Mainly two microvascular pathologies are described: lipohyalinosis of the small perforating arteries feeding deep subcortical structures, and microatheroma formation at the origin of penetrating arteries from major cerebral arteries. Frequent locations for SVD include the basal ganglia, the corona radiata, the internal capsule, the pons, and the thalamus.[8] Infarctions due to SVD are typically small lacunar infarcts and might account for the so-called lacunar syndromes. Historically, several these lacunar syndromes have been described, the most common ones being pure motor stroke, pure sensory stroke, ataxic hemiparesis, sensorimotor stroke, and dysarthria-clumsy hand syndrome. However, these syndromes can as well result from different stroke types, e.g., small embolic strokes.
Stroke of Other Determined Etiology
Stroke of other determined etiology includes, amongst others, extracranial or intracranial arterial dissections, stroke caused by vasculitis, coagulation disorders, or hematological diseases. An overview of the most frequent “other etiologies” is given in [Table 1]. Especially in the case of a stroke at a young age without classical risk factors, these etiologies should be considered and specific diagnostic tests should be initiated.
Table 1
Overview of strokes caused by other determined etiology
|
Cause
|
|
Dissection of cerebral arteries
- Spontaneous dissection of the cervical carotid artery or vertebral artery
- Spontaneous dissection of intracranial arteries
- Dissection in the context of connective tissue diseases (e.g., Ehlers–Danlos syndrome, Marfan syndrome, Loeys–Dietz syndrome, fibromuscular dysplasia)
|
|
Vasculitis
- Primary angiitis of the central nervous system (PACNS)
- Systemic vasculitis/vasculopathy (e.g., Takayasu arteritis, cranial arteritis, lupus erythematosus, panarteritis nodosa, granulomatosis with polyangiitis, ANCA-associated vasculitis, Churg–Strauss syndrome, cryoglobulinemia, Henoch–Schönlein purpura, sarcoidosis, M. Behçet, Sjögren syndrome, microscopic polyangiitis)
- Infectious/parainfectious vasculitis (lues, hepatitis B/C, HIV, CMV, VZV, tuberculosis, bacterial/viral meningitis)
|
|
Coagulation disorders
- Antithrombin deficiency
- Protein C deficiency, protein S deficiency
- Factor V Leiden mutation
- Prothrombin gene mutation
- Antiphospholipid syndrome (APS)
- Paraneoplastic coagulation disorders
|
|
Hematological diseases
- Sickle cell anemia
- Thalassemia
- Polycythemia vera
- Essential thrombocythemia
- Thrombotic thrombocytopenic purpura (TTP)
- Intravascular lymphoma
- Paroxysmal nocturnal hemoglobinuria
|
|
Cardiac causes
- Endocarditis
- Patent foramen ovale (PFO)
- Cardiomyopathy
- Congenital heart defects (atrial septal defect, ventricular septal defect, valve defect)
- Atrial myxoma
|
|
Hereditary diseases
- CADASIL
- MELAS
- Fabry's disease
|
|
Infections
- Parainfectious
|
|
Medicines and drugs
- Heparin-induced thrombocytopenia (HIT)
- Hormonal contraception
- Cocaine, amphetamines, heroin
|
|
Moyamoya disease
|
|
Susac syndrome
|
|
Migraine
|
|
Colitis ulcerosa
|
|
Pregnancy
- Eclampsia, preeclampsia, coagulation disorders in pregnancy
|
Abbreviations: ANCA, antineutrophil cytoplasmic antibody; CMV, cytomegalovirus; HIV, human immunodeficiency virus; VZV, varicella-zoster virus.
Stroke of Undetermined Etiology
Finally, in a relevant proportion of ischemic stroke, no specific etiology can be determined. Strokes of undetermined etiology, also known as cryptogenic strokes, are thought to comprise up to 25% of all ischemic strokes, with a higher proportion in younger stroke populations. This includes patients in whom a complete workup screening for cardiac causes, intracranial or extracranial artery stenosis, and other rare determined causes has been unrevealing. However, there is plausible evidence that most cryptogenic strokes are likely to be of thromboembolic origin. Therefore, the clinical construct of “embolic stroke of undetermined source” (ESUS) was established to identify patients with nonlacunar cryptogenic ischemic strokes in whom embolism was the likely stroke mechanism to guide randomized controlled trials of oral anticoagulation (OAC) in these patients.[9]
Diagnosis and Acute Treatment
Acute diagnosis of stroke comprises rapid physical examination, recording of vital parameters and basal laboratory parameters, and rapid brain imaging using either computed tomography (CT) or magnetic resonance imaging (MRI). After exclusion of intracerebral bleeding, intravenous thrombolysis can be performed within 4.5 hours after the onset of symptoms or based on findings of advanced brain imaging by either MRI or perfusion CT using “DWI-FLAIR mismatch” or “penumbral imaging” if the onset of symptoms is beyond 4.5 hours or unknown (“wake-up stroke”).[10]
[11] Subsequently, or primarily, if thrombolysis is contraindicated, mechanical recanalization should be performed in patients with large-vessel occlusions.[12]
The subacute assessment of patients who have suffered a stroke mainly aims to determine the precise etiology so as to guide effective secondary prevention. Standard diagnostic measures include ultrasound examination of extracranial and intracranial arteries, cardiac diagnostic using electrocardiography (ECG), long-term ECG (for at least 24 hours), and echocardiography, and systematic screening for cardiovascular risk factors such as blood pressure monitoring and laboratory parameters (e.g., blood glucose, cholesterol; see [Table 2]). Of course, other cardiovascular risk factors such as smoking and family history should be evaluated as well. In most cases of stroke in adults with a vascular risk profile, these diagnostic procedures lead to an etiological classification. If not, specific examinations should be added (e.g., specific laboratory tests or lumbar puncture for vasculitis screening).
Table 2
Standard diagnostic measures for ischemic stroke in adults
|
Diagnostic measures
|
Parameters, pathological findings
|
|
Brain imaging (CT or MRI)
|
- Detection/exclusion of intracerebral bleeding
- Localization of ischemic infarcts
- Demarcated cerebral infarcts
- “DWI-FLAIR mismatch,” “penumbral imaging” (“wake-up stroke”)
|
|
CT angiography or MR angiography
|
- Detection of occlusions or stenosis of large-sized and medium-sized arteries in atherosclerosis
- Dissections
|
|
Ultrasound examination of extracranial and intracranial arteries
|
- Detection of large-artery atherosclerosis
- Dissections
|
|
ECG, long-time ECG
|
- Detection of cardiac arrhythmias
|
|
Echocardiography
|
- Heart failure, valvular deficiency, patent foramen ovale (PFO)
|
|
Laboratory tests
|
- Assessment of hematological diseases, liver dysfunction or kidney dysfunction, coagulation disorders, hypercholesterolemia, diabetes mellitus
|
|
Blood pressure monitoring
|
- Arterial hypertension
|
Abbreviations: CT, computed tomography; ECG, electrocardiography; MR, magnetic resonance.
Secondary Prevention
Secondary prevention of stroke includes strategies to reduce the risk of stroke recurrence among patients who had previously presented with a stroke or TIA. Management strategies, which should be specific to the underlying etiology, include the use of antiplatelet or anticoagulant drugs, risk factor modification, carotid surgery, and carotid artery stenting.
Antiplatelet Therapy
Antiplatelet therapy is the basis of secondary prevention for noncardioembolic ischemic stroke or TIA. There are different types of approved antiplatelet drugs in Germany which include aspirin monotherapy, the combination of aspirin and dipyridamole, and thienopyridines (clopidogrel and ticlopidine). Ticlopidine is associated with an increased risk of neutropenia and therefore not generally used in clinical practice. As of today, there is no evidence of a benefit of antiplatelet treatment with prasugrel or ticagrelor, and prasugrel is formally contraindicated with recent stroke. The Antithrombotic Trialists' collaboration meta-analysis of secondary preventive antiplatelet therapy showed a relative risk reduction for the combined endpoint stroke, myocardial infarction, and death of approximately 22%.[13] Antiplatelet therapy should be initiated within 24 hours of admission and continued lifelong.
The most commonly used antiplatelet agent is aspirin. Aspirin is a cyclooxygenase inhibitor that blocks the formation of thromboxane A2 and therefore reduces platelet aggregation. Aspirin lowers the risk of stroke by approximately 15% and the preventive effect is given across doses from 50 and 1,500 mg/d.[14] By contrast, bleeding complications and gastrointestinal side effects are dose-dependent and their frequency significantly increased with higher doses of aspirin.[15] Currently, 100 mg aspirin per day is recommended in Germany as well as in most European countries.
As an alternative to aspirin, the thienopyridine clopidogrel is used in clinical practice. Thienopyridines are adenosine diphosphate (ADP) receptor blockers that inhibit platelet activation and aggregation induced by ADP. Clopidogrel was compared with aspirin in the CAPRIE trial.[16] Patients with stroke, myocardial infarction, or peripheral vascular disease were randomized to aspirin 325 mg/d or clopidogrel 75mg/d. The results indicate that clopidogrel is more effective than aspirin in reducing the combined risk of ischemic stroke, myocardial infarction, or vascular death in patients with atherosclerotic vascular disease. However, in a subgroup analysis of patients with previous stroke, the difference in relative-risk reduction between clopidogrel and aspirin was not statistically significant. The incidence of side effects among both groups was comparable, with a slightly higher rate of gastrointestinal bleeding in patients who received aspirin. It has to be considered that the action of clopidogrel is dependent on variable genetically determined metabolic activation. Therefore, in some cases treatment failure might occur.
The combination of aspirin and dipyridamole is no longer used in clinical practice. Therefore, a detailed description is not part of this review.
Nevertheless, the benefit of aspirin and clopidogrel in the secondary prevention of ischemic stroke is limited. Therefore, more intensive antiplatelet therapy through a different mechanism of action may be more effective at reducing the risk of recurrent ischemia. The SOCRATES study[17] investigated whether ticagrelor may be a more effective antiplatelet therapy than aspirin for the prevention of recurrent stroke and cardiovascular events. Ticagrelor is a potent antiplatelet agent that reversibly binds and inhibits the P2Y12 receptor on platelets. However, in conclusion, ticagrelor was not found to be superior to aspirin in reducing the risk of the composite end point, but there were more instances of dyspnea and minor bleeding in the ticagrelor group.
Long-term double platelet inhibition is not generally recommended, but there are recent findings on risk reduction in minor ischemic stroke (stroke with mild, nondisabling neurological deficits) or TIA by short-term treatment with the combination of aspirin and clopidogrel. The POINT study[18] investigated whether a treatment with aspirin and clopidogrel reduced the rate of recurrent stroke during the first 3 months after a minor stroke or TIA compared with aspirin monotherapy. The results revealed that patients who received a combination of clopidogrel and aspirin had a lower risk of a composite of ischemic stroke, myocardial infarction, or death from ischemic vascular causes. However, those patients had a higher risk of major hemorrhage than patients who received aspirin alone during the 90-day trial period. As a result, the German Stroke Society, in line with recent recommendations published in the British Medical Journal, recommends a short time (10–21 days) combined treatment with aspirin and clopidogrel in these patients.[19]
Oral Anticoagulation
Patients with ischemic stroke or TIA with proven AF should receive OAC. Additional antithrombotic agents should not be used in secondary prevention in patients with AF, unless there is a cardiological indication. Ischemic strokes based on AF are often severe and surviving patients have a high risk of recurrent stroke. The risk of embolism in patients with AF depends on the number of additional risk factors. These include heart failure, hypertension, age >65 or >75 years, diabetes, previous stroke/TIA/systemic embolism, vascular disease, and female gender. In clinical practice, the CHA2DS2-VASc score is used for risk estimation.[20] Before starting an OAC therapy, the risk of bleeding has to be established. Risk factors for the occurrence of bleeding in patients with AF are hypertension, pathological kidney or liver values, stroke, bleeding, an unstable international normalized ratio (INR) in patients on vitamin K antagonist (VKA) therapy, age >65 years, drugs, and alcohol. The HAS-BLED score has been established for estimating the risk of bleeding.[21]
For decades, VKAs have been the only drugs available for OAC in AF. VKA therapy significantly reduces the risk of stroke compared with aspirin or no therapy.[22] However, the use of VKAs is limited by the narrow therapeutic window, frequent monitoring, and dose adjustments. Nowadays, non-VKA oral anticoagulants (NOACs) are suitable alternatives to VKAs for stroke prevention in AF and are recommended as first-line therapy in patients with nonvalvular AF by the European Society of Cardiology (ESC).[23] NOACs are as effective as VKAs with a lower risk of life-threatening and intracranial hemorrhage.[24]
[25]
[26]
[27] Compared with VKAs, NOACs do not need regular anticoagulation monitoring. Approved NOACs in AF are the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, and the thrombin inhibitor dabigatran. A specific antidote (idarucizumab) is available for dabigatran. A specific antidote for factor Xa inhibitors (andexanet alfa) has just recently been approved in the European Union. Kidney function should be regularly monitored in AF patients with OAC to allow dose adaptation for those on NOACs. A creatinine clearance <30 mL/min is a contraindication for dabigatran and a clearance <15 mL/min for rivaroxaban, apixaban, and edoxaban.
Besides the classical indication for OAC after stroke, dissection of extracerebral and intracerebral arteries is often considered as an indication for transient OAC. So far, only one randomized study on secondary prevention of ischemic insults after cerebral artery dissection is available.[28] It has been shown that the recurrence rate of strokes with antiplatelet or anticoagulation therapy did not differ significantly. For decision making, the majority of findings on dissection have been obtained from observational studies.[29]
[30] Based on the guidelines of the German Society of Neurology, secondary prevention after cerebral artery dissection initially should be performed with antiplatelet therapy. In the case of a microembolic signal in transcranial ultrasound, multiple recurrent embolic infarcts while on antiplatelet therapy or arterial (pseudo-) occlusion with strong poststenotic flow reduction, anticoagulation therapy may be reasonable. Initial anticoagulation should be performed with low-molecular-weight heparin, followed by oral VKA (target INR: 2–3). So far, NOACs have not been approved for this indication.
In addition, OAC has been proposed for secondary stroke prevention in patients with ESUS. Two big trials, RE-SPECT ESUS[31] and NAVIGATE ESUS,[32] have been performed to evaluate the secondary prevention effects of NOACs in patients with ESUS compared with aspirin. RE-SPECT ESUS investigated the effects of dabigatran compared with aspirin. The major finding was that dabigatran did not significantly prevent recurrence of stroke after ESUS better than aspirin. There was no significantly increased risk of severe bleeding compared with aspirin.[31] In NAVIGATE ESUS, effectivity of rivaroxaban compared with aspirin was investigated. In summary, rivaroxaban was not superior to aspirin with regard to the prevention of recurrent stroke after ESUS and was associated with a higher risk of bleeding.[32]
Left Atrial Appendage Occlusion
In patients with AF and contraindications for long-term OAC, e.g., those with a high risk for bleeding, left atrial appendage occlusion may be considered as an alternative therapy option. Left atrial appendage occlusion can be performed during other open-heart surgery or with an interventional catheter-deployed device. Few studies have shown that left atrial appendage occlusion via a catheter-deployed device is noninferior to VKA treatment.[33] However, the procedure can cause serious complications and further controlled trials are ongoing to inform the best use of these devices as well as comparison of left atrial appendage occluders with NOACs.
Blood Pressure Management
High blood pressure is a major risk factor for ischemic stroke; various studies on primary prevention of cardiovascular and cerebrovascular events are available. In 2001, the first study on antihypertensive therapy after stroke or TIA revealed that the use of antihypertensive agents in lowering blood pressure leads to a 28% reduction of a recurrent event.[34] Further studies investigated the effects of specific antihypertensive medication in secondary prevention after ischemic stroke.[35]
[36] The superiority of a specific substance class remains controversial and the primary goal is the achievement of a normal blood pressure. The therapeutic range should be between 120/70 mm Hg and 140/90 mm Hg depending on individual comorbidities and adverse effects.
Hypercholesterolemia
Low-density lipoprotein cholesterol (LDL-C) is a risk marker for ischemic stroke.[37] Several studies showed that statin therapy reduces the risk of stroke recurrence. While initial studies referred to patients with coronary heart disease (CHD), the SPARCL study[38] first showed that patients without CHD also benefit from statin therapy. There is no evidence supporting a specific LDL-C target in stroke secondary prevention. According to the guidelines of the German Society of Neurology, the LDL-C target value should be <100 mg/dL. Another analysis from SPARCL indicates that the protective effect to reduce stroke recurrence and cardiovascular complications is most pronounced when a 50% reduction of LDL-C is achieved during treatment.[39] Thus, for stroke patients it may as well be considered reasonable to follow cardiology guidelines in secondary prevention of myocardial infarction that recommend LDL-C target levels of <70 mg/dL or a reduction by at least 50% of the baseline value in patients at very high cardiovascular risk.
Carotid Artery Stenosis and Reperfusion Interventions
Symptomatic internal carotid artery stenosis is associated with a high risk of early recurrent stroke and there is clear evidence for the benefit of revascularization treatment over conservative therapy, with moderate benefit for patients with 50 to 69% stenosis and strong benefit in ≥70% stenosis.[40]
[41] Two therapeutic procedures are available: carotid endarterectomy (CEA) and carotid artery angioplasty and stenting (CAS). CEA is a surgical intervention involving the removal of atherosclerotic plaque from the internal carotid artery. CAS is a percutaneous, minimally invasive approach to treating carotid artery stenosis. There is evidence that CAS is of comparable benefit to CEA in patients <70 years, while in older patients CAS is associated with a higher risk for death and stroke.[42]
[43]
Patent Foramen Ovale Closure
In stroke patients with no other definite cause of stroke, finding of a PFO raises the question whether this may be the cause of stroke and should receive specific treatment. A PFO can be found in approximately 25% of the healthy population, which makes the finding of a PFO in a stroke patient likely to result from chance. On the other hand, high rates of PFO in younger stroke patients going up to 45% suggest a causal relationship. Especially in patients younger than 55 years with a PFO, the risk of cryptogenic ischemic insult is increased. Based on three studies from 2017,[44]
[45]
[46] interventional closure of PFO in patients between 16 and 60 years with a cryptogenic ischemic stroke and PFO with moderate or pronounced right-left shunt significantly reduced the already low rate of recurrent stroke in these patients. This benefit has to be weighed against a small risk of periprocedural complications including AF. As a consequence, interventional PFO closure should be considered in younger stroke patients with stroke of unknown cause. Results from earlier observational studies as well as recent subgroup analysis of NAVIGATE ESUS suggest that OAC might be superior to antiplatelets for secondary prevention in patients with ESUS and PFO,[47] but further trials are needed to test this hypothesis.
Secondary Prevention of Stroke Due to Coagulation Disorders
Hereditary and acquired thrombophilia may be associated with ischemic stroke. Hereditary thrombophilia, such as factor V Leiden mutation, prothrombin gene mutation G20210A, and deficiencies of protein C, protein S, and antithrombin, is a well-known risk factor for venous thrombosis, but may also be associated with ischemic stroke. The association of thrombophilia with ischemic stroke is much less strong than with venous thrombosis. However, diagnosis of a significant coagulation disorder in a patient with acute ischemic stroke with no other etiology is usually considered to be an indication for OAC. There are no large clinical trials available to guide recommendations for secondary prevention in patients with stroke and coagulation disorder. Antiplatelet therapy is recommended for patients who are found to have abnormal findings on coagulation testing after initial ischemic stroke or TIA if anticoagulation therapy is not administered.[48]
Antiphospholipid syndrome (APS) presents with venous and arterial thrombosis or one of several specific pregnancy complications in the presence of persistent antiphospholipid antibodies.[49] An APS should be suspected in patients with ischemic stroke or TIA who have no alternative explanation for the ischemic event and who have other manifestations of the syndrome such as livedo reticularis, obstetric complications, unexplained thrombocytopenia, or prolongation of a coagulation test. There is no general consensus on optimal antithrombotic therapy of patients with ischemic stroke or TIA who have an antiphospholipid antibody. Antiplatelet therapy is often recommended for patients with ischemic stroke or TIA in whom antiphospholipid antibodies are found but who do not meet the criteria for APS. For patients with ischemic stroke or TIA who fulfill the APS criteria, anticoagulation therapy may be reasonable, considering the risk for recurrent thrombotic event and bleeding complications.[48] Currently, VKAs are the standard treatment for OAC in APS. NOACs are increasingly used for OAC in APS, but do not seem to be as effective as VKAs in patients with high-risk APS including those with arterial embolism and stroke.[50]
Most studies and subsequent recommendations on anticoagulation management for coagulation disorders refer to therapy with heparin or VKAs and there is a lack of more recent knowledge on NOACs. Recently, there are new findings for anticoagulation for cancer-associated venous thromboembolism. So far, low-molecular-weight heparin has been the standard therapy. The Hokusai VTE Cancer Study[51] showed that oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding providing first evidence that thromboembolic events due to coagulations disorders may be adequately treated with NOACs.
